Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

PCSK9 inhibitors are known for slashing LDL cholesterol — but they also lower lipoprotein(a), which most drugs cannot touch. This analysis of the large ODYSSEY OUTCOMES trial asked whether that Lp(a) lowering provides benefit in its own right.

Among nearly 19,000 patients treated after an acute coronary syndrome, baseline Lp(a) predicted future cardiovascular events. The key finding was an independence: when the investigators statistically separated the two effects, both the LDL reduction and the Lp(a) reduction predicted lower event rates on their own. For patients who started with high Lp(a), the Lp(a)-lowering accounted for a meaningful share — up to a quarter — of the drug’s overall benefit.

This is among the first clinical evidence that lowering Lp(a) itself, not just LDL, reduces cardiovascular events. It elevated Lp(a) from a risk marker toward a treatment target — the hypothesis that the dedicated Lp(a)-lowering drugs now in trials are designed to test directly.

We rate the evidence strong. As a pre-specified analysis of a major randomized trial it is high quality, though, being a secondary analysis rather than a trial designed around Lp(a), it is suggestive rather than definitive.